MEDI 4276

Drug Profile

MEDI 4276

Alternative Names: MEDI4276

Latest Information Update: 23 Oct 2015

Price : $50

At a glance

  • Originator MedImmune
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer

Most Recent Events

  • 01 Sep 2015 Phase-I clinical trials in Breast cancer (In adults, Late-stage disease, Second-line therapy or greater) in USA (unspecified route)
  • 01 Sep 2015 Phase-I clinical trials in Gastric cancer (In adults, Late-stage disease, Second-line therapy or greater) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top